Success and Balance promotion CN

Article

Stressed out?

 

Looking for solutions for efficiency and balance? We can help.

 

This guide book brings you the best of Physicians Practice to help you:

 

 

 

Choose from three ordering options:

 

1. Click Here to Buy the Paperback Version

 

2. Click Here to Buy the Kindle e-book

 

3. Click Here to Buy the EPUB Version

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
1 expert is featured in this series.
2 experts are featured in this series.
2 experts are featured in this series.
5 experts are featured in this series
5 experts are featured in this series
2 experts in this video
“If you have a [patient in the] fourth or fifth line, [JNJ-5322] could be a valid drug of choice,” said Rakesh Popat, BSc, MBBS, MRCP, FRCPath, PhD.
2 experts in this video
Earlier treatment with daratumumab may be better tolerated for patients with pretreated MRD-negative multiple myeloma.
The trispecific antibody JNJ-5322 demonstrated superior efficacy vs approved agents in multiple myeloma in results shared at the 2025 EHA Congress.
Related Content